Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Withdrawal of Exubera: a great therapeutic loss?

bs_subtitle

The inexorable progression of type 2 diabetes frequently leads patients to need insulin replacement. Manybarriers exist to starting insulin therapy, including reluctance of patients to accept lifelong injections.Inhalation of insulin has been suggested for many years, and recent advances in technology made thismethod a reality. Exubera was the first inhalable insulin product to launch, and several other inhaledinsulin systems are in development. Inhaled insulin is effective at lowering plasma glucose, and manypatients express a preference to use it over injecting insulin. Concerns over cost-benefit and pulmonaryadverse effects do not allow recommendation of widespread use of this treatment. Nevertheless, it couldbe

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy